Grace Therapeutics' GTx-104 Shows Safety Edge in Phase 3 aSAH Trial

Event summary

  • STRIVE-ON Phase 3 trial results accepted for AAN 2026 presentation on April 21, 2026.
  • GTx-104 showed 19% reduction in clinically significant hypotension vs. oral nimodipine.
  • 29% more patients on GTx-104 had favorable functional outcomes at 90 days.
  • Fewer ICU readmissions, days, and ventilator days observed with GTx-104.
  • No new safety issues identified; adverse events comparable between treatments.

The big picture

Grace Therapeutics' positive Phase 3 results for GTx-104 in aSAH patients highlight the potential of intravenous nimodipine delivery to address significant unmet medical needs. The data suggests advantages in safety, functional outcomes, and hospital resource utilization compared to oral administration. This positions GTx-104 as a potential game-changer in the treatment of this rare and life-threatening condition, with the added benefit of Orphan Drug Designation providing market exclusivity.

What we're watching

Regulatory Pathway
Whether STRIVE-ON data will support successful NDA submission for GTx-104.
Market Differentiation
How GTx-104's safety and efficacy profile will position it against oral nimodipine in aSAH treatment.
Commercialization Timing
The pace at which Grace Therapeutics can leverage these results for potential approval and market entry.